Literature DB >> 28033675

Bacteriophage formulated into a range of semisolid and solid dosage forms maintain lytic capacity against isolated cutaneous and opportunistic oral bacteria.

Teagan L Brown1, Tereen Thomas1, Jessica Odgers1, Steve Petrovski2, Marion Joy Spark1, Joseph Tucci1.   

Abstract

BACKGROUND: Resistance of bacteria to antimicrobial agents is of grave concern. Further research into the development of bacteriophage as therapeutic agents against bacterial infections may help alleviate this problem.
OBJECTIVES: To formulate bacteriophage into a range of semisolid and solid dosage forms and investigate the capacity of these preparations to kill bacteria under laboratory conditions.
METHODS: Bacteriophage suspensions were incorporated into dosage forms such as creams, ointments, pastes, pessaries and troches. These were applied to bacterial lawns in order to ascertain lytic capacity. Stability of these formulations containing phage was tested under various storage conditions. KEY
FINDINGS: A range of creams and ointments were able to support phage lytic activity against Propionibacterium acnes. Assessment of the stability of these formulations showed that storage at 4 °C in light-protected containers resulted in optimal phage viability after 90 days. Pessaries/suppositories and troches were able to support phage lytic activity against Rhodococcus equi.
CONCLUSIONS: We report here the in-vitro testing of semisolid and solid formulations of bacteriophage lytic against a range of bacteria known to contribute to infections of the epithelia. This study provides a basis for the future formulation of diverse phage against a range of bacteria that infect epithelial tissues.
© 2016 Royal Pharmaceutical Society.

Entities:  

Keywords:  bacteriophage; bacteriophage therapy

Mesh:

Substances:

Year:  2016        PMID: 28033675     DOI: 10.1111/jphp.12673

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

Review 1.  Topical application of bacteriophages for treatment of wound infections.

Authors:  Rachel Yoon Kyung Chang; Sandra Morales; Yuko Okamoto; Hak-Kim Chan
Journal:  Transl Res       Date:  2020-03-19       Impact factor: 7.012

Review 2.  Semi-Solid and Solid Dosage Forms for the Delivery of Phage Therapy to Epithelia.

Authors:  Teagan L Brown; Steve Petrovski; Hiu Tat Chan; Michael J Angove; Joseph Tucci
Journal:  Pharmaceuticals (Basel)       Date:  2018-02-26

3.  Characterization and formulation into solid dosage forms of a novel bacteriophage lytic against Klebsiella oxytoca.

Authors:  Teagan L Brown; Steve Petrovski; Dannielle Hoyle; Hiu Tat Chan; Peter Lock; Joseph Tucci
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

Review 4.  Robust Approaches for the Production of Active Ingredient and Drug Product for Human Phage Therapy.

Authors:  Michele Mutti; Lorenzo Corsini
Journal:  Front Microbiol       Date:  2019-10-08       Impact factor: 5.640

Review 5.  Bacteriophages in Natural and Artificial Environments.

Authors:  Steven Batinovic; Flavia Wassef; Sarah A Knowler; Daniel T F Rice; Cassandra R Stanton; Jayson Rose; Joseph Tucci; Tadashi Nittami; Antony Vinh; Grant R Drummond; Christopher G Sobey; Hiu Tat Chan; Robert J Seviour; Steve Petrovski; Ashley E Franks
Journal:  Pathogens       Date:  2019-07-12

Review 6.  Applications for Bacteriophage Therapy during Pregnancy and the Perinatal Period.

Authors:  Lucy L Furfaro; Barbara J Chang; Matthew S Payne
Journal:  Front Microbiol       Date:  2018-01-11       Impact factor: 5.640

Review 7.  Considerations for the Use of Phage Therapy in Clinical Practice.

Authors:  Gina A Suh; Thomas P Lodise; Pranita D Tamma; Jane M Knisely; Jose Alexander; Saima Aslam; Karen D Barton; Erica Bizzell; Katherine M C Totten; Joseph L Campbell; Benjamin K Chan; Scott A Cunningham; Katherine E Goodman; Kerryl E Greenwood-Quaintance; Anthony D Harris; Shayla Hesse; Anthony Maresso; Veronique Nussenblatt; David Pride; Michael J Rybak; Zoe Sund; David van Duin; Daria Van Tyne; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2022-01-18       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.